Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew T Bender

Showing results (41-50 of 41) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 41 results.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 5

Showing results (41-50 of 41) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 41 results.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 5